MannKind Corporation (MNKD)

Market Cap	1.36B
Revenue (ttm)	76.23M
Net Income (ttm)	-97.51M
Shares Out	263.20M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	303.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,369,967
Open	5.20
Previous Close	5.29
Day's Range	5.15 - 5.33
52-Week Range	2.49 - 5.51
Beta	1.67
Analysts	Buy
Price Target	6.22 (+20.08%)
Earnings Date	Feb 23, 2023

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NR...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 348
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD

Financial Performance

In 2021, MannKind's revenue was $75.44 million, an increase of 15.81% compared to the previous year's $65.14 million. Losses were -$80.93 million, 41.4% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $6.22, which is an increase of 20.08% from the latest price.

Price Target

$6.22

(20.08% upside)

Analyst Consensus: Buy